RANDI KATZ: Open Payments
NPI 1952012189 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,125 in 114 payments from 15 companies in 2025. Trend: 2023 $889 · 2024 $2,576 · 2025 $2,125
Food & beverage: $2,125
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 23 | $585 |
| ABBVIE INC. | 14 | $270 |
| Otsuka America Pharmaceutical, Inc. | 17 | $240 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $225 |
| Teva Pharmaceuticals USA, Inc. | 12 | $190 |
| E.R. Squibb & Sons, L.L.C. | 14 | $188 |
| Alkermes, Inc. | 7 | $135 |
| Axsome Therapeutics, Inc. | 5 | $87 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Tris Pharma Inc | 2 | $38 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, REXULTI, COBENFY, ARISTADA, AUSTEDO XR, UZEDY.
Industry payments across TX — which companies pay providers there.
